Trial Number
166-21
Condition
Esophageal Cancer
Participant Age Range
18 years and older
Participant Gender
Any
Enrolling Participants
Yes
Overview
“A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)”
This is a Phase 3, randomized, double-blind, placebo-controlled multi-site study ofpembrolizumab in combination with dCRT versus placebo in combination with dCRT in participants with histologically or cytologically confirmed diagnosis of cTX N+ M0 or cT2-T4a NX M0 ESCC (as defined by AJCC 8th edition), GEJC, EAC, or histologically or cytologically confirmed diagnosis of cTX N+ M1 cervical or upper thoracic esophageal carcinoma with supraclavicular lymph node metastases only and who are candidates for dCRT.